FDA Gives Beckman Coulter EUA for its Interleukin-6 Assay
October 01 2020 - 3:47PM
Dow Jones News
By Stephen Nakrosis
Beckman Coulter on Thursday said its Access Interleukin-6 assay,
which can help physicians determine the risk of intubation with
mechanical ventilation in Covid-19 patients, was given Emergency
Use Authorization by the U.S. Food and Drug Administration.
"An assay that helps identify patients at risk for respiratory
failure and intubation in the care pathway has the potential to
significantly improve Covid-19 patient care and outcomes," said
Shamiram R. Feinglass, chief medical officer for Beckman Coulter,
adding, "In conjunction with clinical findings and the results of
other laboratory testing, this assay provides clinicians with vital
information enabling them to make decisions on how to manage these
critically ill patients."
The company said preliminary studies have shown that the IL-6
level is elevated in patients with severe Covid-19 and may
contribute to severe inflammatory response.
Beckman Coulter is an operating company of Danaher Corp.
--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
October 01, 2020 15:32 ET (19:32 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Danaher (NYSE:DHR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Danaher (NYSE:DHR)
Historical Stock Chart
From Apr 2023 to Apr 2024
